Clinical Trials Browser

Advanced Breast Cancer

NCT05554354 2026-03-03

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Phase 2 Terminated

1 enrolled

Breast

Anatomic Stage IV Breast Cancer AJCC v8

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast

Breast Cancer Metastatic

NCT03289039 2026-01-22

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2 Terminated

21 enrolled 15 charts

Breast

Breast Neoplasms

NCT05082025 2026-01-09

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Phase 2 Terminated

7 enrolled 10 charts

Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT06408168 2026-01-05

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Phase 2 Terminated

6 enrolled

Carcinoma, Lobular

NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Phase 2 Terminated

64 enrolled 21 charts

Breast

Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast

Breast Neoplasms

NCT04899349 2024-10-09

EPIK-B4

Phase 2 Terminated

2 enrolled 8 charts

Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT05966584 2024-08-29

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Phase 2 Terminated

1 enrolled 5 charts

Breast

Breast Neoplasms, Exanthema

NCT04862143 2024-06-20

TELEPIK

Phase 2 Terminated

2 enrolled 10 charts

Breast

Advanced Breast Cancer

NCT04738292 2024-05-03

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Phase 2 Terminated

11 enrolled 10 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT02540330 2024-04-03

007

Phase 2 Terminated

3 enrolled 7 charts

Breast

Female Breast Carcinoma

NCT01953926 2024-03-12

SUMMIT

Phase 2 Terminated

582 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03322215 2024-03-08

PASIPHAE

Phase 2 Terminated

42 enrolled

Breast

Breast Cancer Metastatic

NCT05932667 2023-12-21

DEMETER

Phase 2 Terminated

1 enrolled

Breast

Breast Neoplasms

NCT04305236 2023-06-06

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

Phase 2 Terminated

1 enrolled 5 charts

Breast

Breast Neoplasms

NCT03386162 2022-11-28

SAFIR-PI3K

Phase 2 Terminated

31 enrolled

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT03584009 2022-06-28

Veronica

Phase 2 Terminated

103 enrolled 19 charts

Breast

Breast Neoplasms

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Phase 2 Terminated

2 enrolled 7 charts

Breast

Breast Neoplasms

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Phase 2 Terminated

3 enrolled 4 charts

Breast

Breast Neoplasms

NCT02569801 2021-04-23

HydranGea

Phase 2 Terminated

71 enrolled 12 charts

Breast

Breast Neoplasms

NCT00570258 2021-03-30

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Phase 2 Terminated

27 enrolled 7 charts

Breast

Breast Neoplasms

NCT00138125 2020-10-19

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Phase 2 Terminated

2 enrolled 5 charts

Breast

Breast Neoplasms

NCT03241810 2020-09-02

SHERBOC

Phase 2 Terminated

22 enrolled 16 charts

Breast

Breast Neoplasms

NCT02374099 2018-12-14

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Phase 2 Terminated

97 enrolled 18 charts

Breast

Breast Neoplasms

NCT00722072 2018-02-26

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Phase 2 Terminated

12 enrolled 7 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00932152 2017-10-19

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

3 enrolled 6 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00592007 2017-06-06

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Phase 2 Terminated

7 enrolled 3 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00752986 2016-12-05

ZACFAST

Phase 2 Terminated

39 enrolled 7 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01528345 2016-07-11

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Phase 2 Terminated

97 enrolled 10 charts

Breast

Breast Neoplasms

NCT00372996 2015-10-28

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Phase 2 Terminated

219 enrolled 11 charts

Breast

Breast Neoplasms

NCT00217464 2015-04-16

Fulvestrant in Treating Patients With Recurrent Prostate Cancer

Phase 2 Terminated

17 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

NCT00183963 2014-05-22

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

Phase 2 Terminated

4 enrolled 8 charts

Breast

Breast Neoplasms

NCT00206414 2013-02-05

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

Phase 2 Terminated

15 enrolled

Breast

Breast Neoplasms

NCT01233947 2012-01-09

Study of AFP464 +/- Faslodex in ER + Breast Cancer

Phase 2 Terminated

7 enrolled

Breast

Breast Neoplasms

NCT00774878 2011-03-03

Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer

Phase 2 Terminated

18 enrolled

Breast

Breast Neoplasms

Clinical Trials

A Study of Lerociclib in Participants With Advanced Breast Cancer

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

AMEERA-3

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

EPIK-B4

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

TELEPIK

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

007

SUMMIT

PASIPHAE

DEMETER

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

SAFIR-PI3K

Veronica

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Phase II Study of Everolimus Beyond Progression

HydranGea

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

SHERBOC

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

ZACFAST

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Fulvestrant in Treating Patients With Recurrent Prostate Cancer

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

Study of AFP464 +/- Faslodex in ER + Breast Cancer

Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer